Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneratio

Phase 3

Completed

• Conditions: Age-related macular degeneration; AMD; 10042261

• Registration Number: NL-OMON43671
• Lead Sponsor: Allergan Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

- Diagnosis of age-related macular degeneration in at least 1 eye
- Best corrected visual acuity of 20/40 to 20/320 in the study eye
- Best corrected visual acuity of 20/200 or better in the non-study eye

Exclusion Criteria

- History of vitrectomy, macular surgery, or glaucoma surgery in the study eye
- Cataract or refractive surgery in the study eye within the last 3 months

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Percentage of Patients with Best Corrected Visual Acuity (BCVA) Change from<br /><br>Baseline *15 Letters in the Study Eye at Baseline and Week 52</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>* Change from Baseline in BCVA in the Study Eye at Week 52<br /><br>* Change from Baseline in Central Retinal Thickness (CRT) in the Study Eye at<br /><br>Week 52<br /><br>* Percentage of Patients with a BCVA Gain of *15 Letters in the Study Eye on<br /><br>the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale at Week 52<br /><br>* Change from Baseline in the National Eye Institute Visual Functioning<br /><br>Questionnaire-25 (NEI-VFQ-25) Composite Score at Week 52</p><br>